Risks associated with hepatitis A and hepatitis B in patients with hepatitis C.
Individuals with hepatitis C virus (HCV) are at risk for acquiring hepatitis A virus (HAV) or hepatitis B virus (HBV) because of shared risk factors. A number of organizations recommend vaccination against HAV and HBV for patients with HCV. The rationale for vaccinating these patients is to prevent hepatic superinfections. Acute HAV superinfection causes more severe disease, acute hepatic failure, and higher fatality rates in patients with underlying chronic liver disease, specifically chronic HBV infection and chronic HCV infection. Available data, although limited, suggest that HBV coinfection with HAV and HCV causes more severe hepatic injury than infection with HAV or HCV alone. At standard doses, hepatitis A and hepatitis B vaccines are safe and immunogenic in patients with mild-to-moderate hepatitis C or chronic liver disease. Regardless of disease severity, vaccination should be routinely administered to patients upon diagnosis of HCV infection. Early vaccination is important because response to vaccination is reduced as liver disease progresses. Prevaccination and postvaccination serology testing is recommended in specific populations. A new combination hepatitis A and hepatitis B vaccine has been shown to be as safe and effective as monovalent hepatitis A and B vaccines and is currently under review by the United States Food and Drug Administration. A combination vaccine would offer ease of administration and convenience and could increase compliance in patients with hepatitis C or other chronic liver disease: two groups that should be more aggressively targeted by healthcare professionals.
Koff
R S
RS
University of Massachusetts Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA. koffr@ummhc.org
D000328:Adult; D002423:Cause of Death; D005260:Female; D006506:Hepatitis A / Q000401:mortality / Q000517:prevention & control / Q000635:transmission*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage; D006509:Hepatitis B / Q000401:mortality / Q000517:prevention & control / Q000635:transmission*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006526:Hepatitis C / Q000401:mortality / Q000517:prevention & control / Q000635:transmission*; D006801:Humans; D008297:Male; D012307:Risk Factors; D015163:Superinfection / Q000401:mortality / Q000517:prevention & control / Q000635:transmission*; D015996:Survival Rate
D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines